Zur Kurzanzeige

2012-12-28Zeitschriftenartikel DOI: 10.1007/s10198-012-0452-1
Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany
dc.contributor.authorUltsch, Bernhard
dc.contributor.authorKöster, Ingrid
dc.contributor.authorReinhold, Thomas
dc.contributor.authorSiedler, Anette
dc.contributor.authorKrause, Gérard
dc.contributor.authorIcks, Andrea
dc.contributor.authorSchubert, Ingrid
dc.contributor.authorWichmann, Ole
dc.date.accessioned2018-05-07T18:41:42Z
dc.date.available2018-05-07T18:41:42Z
dc.date.created2015-12-09
dc.date.issued2012-12-28none
dc.identifier.otherhttp://edoc.rki.de/oa/articles/rebz3pEHTZrG/PDF/297q6Dfh0ov1.pdf
dc.identifier.urihttp://edoc.rki.de/176904/2207
dc.description.abstractAfter acquiring a varicella virus infection, the virus can reactivate and cause herpes zoster (HZ)—a painful skin rash. A complication of HZ is long-term persistence of pain after the rash has resolved (so-called postherpetic neuralgia, PHN). We aimed to describe the epidemiology of HZ/PHN and to estimate HZ/PHN-related costs in the German statutory health insurance (SHI) system (~85 % of the total population). Treatment data of one large SHI was utilized, containing data on approximately 240,000 insured and their utilisation of services in 2004–2009. Identification of HZ- and PHN-cases was performed based on ‘International Statistical Classification of Diseases’ and specific medications using a control-group design. Incidences per 1,000 person-years (PY) and cost-of-illness for 1 year following HZ-onset considering the payer and societal perspective were calculated. All amounts were inflated to 2010 Euros. Population-figures were standardised and extrapolated to the total SHI-population in Germany in 2010. A mean annual incidence of 5.79 HZ-cases per 1,000 PY was observed, translating into an estimated 403,625 HZ-cases per year in the total SHI-population. Approximately 5 % of HZ-cases developed PHN. One HZ-case caused on average €210 and €376 of costs from the payer and societal perspective, respectively. The development of PHN generated additional costs of €1,123 (€1,645 societal perspective). Total annual HZ/PHN-related costs were estimated at €182 million (€105 million) to society (payer). HZ and PHN place a considerable burden on the German SHI-system. Since HZ-vaccines will soon be available, a health-economic evaluation of these vaccines should be conducted.eng
dc.language.isoger
dc.publisherRobert Koch-Institut, Infektionsepidemiologie
dc.subjectHumanseng
dc.subjectGermany/epidemiologyeng
dc.subjectAbsenteeismeng
dc.subjectHealth Expenditures/statistics & numerical dataeng
dc.subjectHealth Services/economicseng
dc.subjectHerpes Zoster/economicseng
dc.subjectHerpes Zoster/prevention & controleng
dc.subjectHerpes Zoster Vaccine/administration & dosageeng
dc.subjectHerpes Zoster Vaccine/economicseng
dc.subjectModels Economiceng
dc.subjectNeuralgia Postherpetic/economicseng
dc.subjectNeuralgia Postherpetic/prevention & controleng
dc.subject.ddc610 Medizin
dc.titleEpidemiology and cost of herpes zoster and postherpetic neuralgia in Germany
dc.typeperiodicalPart
dc.identifier.urnurn:nbn:de:0257-10042199
dc.identifier.doi10.1007/s10198-012-0452-1
dc.identifier.doihttp://dx.doi.org/10.25646/2132
local.edoc.container-titleThe European Journal of Health Economics
local.edoc.container-textOriginally published as: Ultsch, B., Köster, I., Reinhold, T., Siedler, A., Krause, G., Icks, A., Schubert, I., Wichmann, O. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany (2013) European Journal of Health Economics, 14 (6), pp. 1015-1026.
local.edoc.fp-subtypeArtikel
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttp://link.springer.com/article/10.1007%2Fs10198-012-0452-1
local.edoc.container-publisher-nameSpringer
local.edoc.container-volume14
local.edoc.container-issue6
local.edoc.container-year2013

Zur Kurzanzeige